|Articles|June 1, 2003

June 2003
Volume 9
Issue 6

High-Versus Low-dose Angiotensin Converting Enzyme Inhibitor Therapy in the Treatment of Heart Failure: An Economic Analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial

Author(s)J. Sanford Schwartz, MD, Y. Richard Wang, MD, PhD, John G. F. Cleland, MD

Download PDF: High-Versus Low-dose Angiotensin Converting Enzyme Inhibitor Therapy in the Treatment of Heart Failure: An Economic Analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial

Articles in this issue

over 22 years ago

Article

A Randomized Trial of an Acid-peptic Disease Management Program in a Managed Care Environment

over 22 years ago

Article

When Money Is Saved by Reducing Healthcare Costs, Where Do US Primary Care Physicians Think the Money Goes?

over 22 years ago

Article

Care Management Interventions for Older Patients with Congestive Heart Failure

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

ByNate C. Apathy, PhD

January 27th 2026

Building Trust: Public Priorities for Health Care AI Labeling

ByMorgan L. Sielaff, BS,Jodyn Platt, PhD, MPH,Sean Tan, MPP,Kerry A. Ryan, MA,Paige Nong, PhD,Sharon L. R. Kardia, PhD

January 27th 2026

Ambient AI Tool Adoption in US Hospitals and Associated Factors

ByFreddie Yang, MA,Ilana Graetz, PhD

January 27th 2026

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

ByTaylor I. Bucy, PhD,John P. McHugh, PhD,Dori A. Cross, PhD

January 26th 2026

Specialty and Operator Status Influence Electronic Health Record Use Variation

ByPhillip D. Jenkins, MD,Gary Grunkemeier, PhD,Elizabeth Weirich, DO,An Dinh, MS,Ruchi Thanawala, MD, MS,Jeffrey A. Gold, MD,Julie Doberne, MD, PhD

January 22nd 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

High-Versus Low-dose Angiotensin Converting Enzyme Inhibitor Therapy in the Treatment of Heart Failure: An Economic Analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial

Articles in this issue

Newsletter

Related Content

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

Building Trust: Public Priorities for Health Care AI Labeling

Ambient AI Tool Adoption in US Hospitals and Associated Factors

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

Specialty and Operator Status Influence Electronic Health Record Use Variation

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Trending on AJMC

CMS Proposes Nearly Flat 2027 Medicare Advantage Payment Rates

ICE Presence in Minnesota Health Care Settings Threatens Access to Essential Medical Care

FAQ: What to Know About the Vaccine Rollbacks and What They Mean Long-Term

Ambient AI Tool Adoption in US Hospitals and Associated Factors

Building Trust: Public Priorities for Health Care AI Labeling